E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Clofarabine in the treatment of myelodysplastic syndromes.
TL;DR: In addition to providing a valuable treatment option for pediatric ALL patients, clofarabine has substantial activity against MDS and is well tolerated by elderly patients, thus rendering it a potential therapeutic option for MDS.
Journal ArticleDOI
Myelodysplastic/Myeloproliferative Neoplasms, Unclassifiable (MDS/MPN, U): Natural History and Clinical Outcome By Therapeutic Approach
Courtney D. DiNardo,Naval Daver,Nitin Jain,Naveen Pemmaraju,Carlos E. Bueso-Ramos,Cheng Yin,Sherry Pierce,Elias Jabbour,Alfonso Quintás-Cardama,Jorge E. Cortes,Hagop M. Kantarjian,Guillermo Garcia-Manero,Srdan Verstovsek +12 more
TL;DR: A uniquely favorable outcome was seen in the 11 patients presenting with a PLT count ≥ 450 x 10⁹/L, with median OS 52, which imparted a statistically significant classification for the MDS/MPN-U cohort, with a median OS by IPSS score of 15.4.
Journal ArticleDOI
Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant
Bachar Samra,Hagop M. Kantarjian,Koji Sasaki,Ahmad S. Alotaibi,Marina Konopleva,Susan O'Brien,Alessandra Ferrajoli,Rebecca Garris,Cesar Nunez,Tapan M. Kadia,Nicholas J. Short,Elias Jabbour +11 more
TL;DR: TKI discontinuation outside of HSCT in Ph-positive ALL in the setting of compelling toxicity may be safe only among a highly selected group of patients with deep and prolonged DMR undergoing close and frequent monitoring.
Journal ArticleDOI
B-cell lymphoma/leukaemia 11B (BCL11B) expression status helps distinguish early T-cell precursor acute lymphoblastic leukaemia/lymphoma (ETP-ALL/LBL) from other subtypes of T-cell ALL/LBL
Hong Fang,Wei Wang,Siba El Hussein,Kiyomi Morita,Hannah C. Beird,Akash Mitra,Sanam Loghavi,Pei Lin,Elias Jabbour,Joseph D. Khoury +9 more
TL;DR: In this paper, the authors investigated BCL11B expression by immunohistochemistry in T-lymphoblastic leukaemia/lymphoma (T-ALL/LBL) (n = 115).
Journal ArticleDOI
Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission.
Iman Abou Dalle,Iman Abou Dalle,Hagop M. Kantarjian,Farhad Ravandi,Naval Daver,Xuemei Wang,Elias Jabbour,Zeev Estrov,Courtney D. DiNardo,Naveen Pemmaraju,Alessandra Ferrajoli,Nitin Jain,Sa A. Wang,Nadya Jammal,Gautam Borthakur,Kiran Naqvi,Sarah Gwen Pelletier,Sherry Pierce,Michael Andreeff,Guillermo Garcia-Manero,Jorge E. Cortes,Tapan M. Kadia +21 more
TL;DR: In this paper, the efficacy of lenalidomide maintenance was evaluated in patients with high-risk acute myeloid leukemia (AML) who had achieved their first or second remission after induction chemotherapy and at least 1 consolidation cycle and who were not candidates for immediate ASCT.